

Supplementary Table 1: Search strategy across included databases

Database	Search String	Results
MEDLINE	("Prostatic Neoplasms"[MeSH] OR "Prostate Cancer"[tiab] OR "Prostatic Cancer"[tiab] OR "Prostate Neoplasm*"[tiab] OR "Metastatic Prostate Cancer"[tiab] OR "Castration-Resistant Prostate Cancer"[tiab] OR "Hormone-Refractory Prostate Cancer"[tiab] OR mCRPC[tiab] OR mHSPC[tiab]) AND ("Docetaxel"[MeSH] OR docetaxel[tiab] OR taxotere[tiab]) AND (weekly[tiab] OR biweekly[tiab] OR "bi-weekly"[tiab] OR "two-weekly"[tiab] OR fortnightly[tiab] OR triweekly[tiab] OR "three-weekly"[tiab] OR schedule*[tiab] OR dosing[tiab] OR regimen*[tiab] OR administration[tiab] OR dose-intensity[tiab]))	1,176
Embase	('prostate cancer'/exp OR 'prostate carcinoma':ti,ab OR 'metastatic prostate cancer':ti,ab OR 'castration resistant prostate cancer':ti,ab) AND ('docetaxel'/exp OR docetaxel:ti,ab OR taxotere:ti,ab) AND (weekly:ti,ab OR biweekly:ti,ab OR 'two weekly':ti,ab OR fortnightly:ti,ab OR triweekly:ti,ab OR 'three weekly':ti,ab OR dosing:ti,ab OR regimen*:ti,ab OR schedule*:ti,ab)	2,538
Cochrane CENTRAL	(prostate cancer OR prostatic neoplasm) AND (docetaxel) AND (weekly OR biweekly OR two weekly OR fortnightly OR triweekly OR three weekly)	176

Supplementary Table 2: Evaluation of the quality of the 7 included cohort studies by using the Newcastle-Ottawa Scale

Studies	Selection				Comparability		Exposure or outcome			No. of star
	1	2	3	4	1	2	1	2	3	
Berthold et al. (2008)	*	*	*	*	*		*	*		7
Kim et al. (2017)	*	*	*	*	*		*	*		7
Martinez-Recio et al. (2022)	*	*	*	*	*	*	*	*	*	9
Samar et al. (2020)	*	*	*	*	*		*	*		7
Sayin et al. (2022)		*	*	*	*		*	*		6
Shimura et al. (2020)	*	*	*	*	*		*	*		7
Yuk et al. (2024)	*	*	*	*	*	*	*	*	*	9

Supplementary Table 3. Identifying local inconsistency via indirect versus direct comparisons and the use of a node splitting approach.

Outcome	Comparison	p-value
PSA Response Rate	2:1	0.7874
	3:1	0.5070
	2:3	0.1670
Time for treatment failure or progression	2:1	< 0.0001
	3:1	< 0.0001
	2:3	NA
Hepatotoxicity	2:1	0.4600
	3:1	NA
	2:3	0.4600
Vomiting	2:1	NA
	3:1	NA
	2:3	NA

Any Adverse Events	2:1	0.8830
	3:1	0.8830
	2:3	NA
Thrombocytopenia	2:1	NA
	3:1	NA
	2:3	NA
Anemia	2:1	NA
	3:1	NA
	2:3	NA
Arthralgia	2:1	NA
	3:1	NA
	2:3	NA
Neuropathy	2:1	0.3301
	3:1	0.5244
	2:3	0.2037
Neutropenia	2:1	NA
	3:1	NA
	2:3	NA
Fatigue	2:1	0.8587
	3:1	0.5412
	2:3	0.3718
Febrile neutropenia	2:1	NA
	3:1	NA
	2:3	NA

Nausea	2:1	NA
	3:1	NA
	2:3	NA
Diarrhea	2:1	NA
	3:1	NA
	2:3	NA
Anorexia	3:2	NA


Note: Weekly, biweekly, and triweekly docetaxel therapy are referred to as 1, 2, and 3, respectively. P-values lower than 0.05 indicate that local inconsistency was observed in the specific comparison. Statistically significant p-values presented in bold. NA represents that there is either no direct or indirect evidence available for that specific comparison.

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	Hervonen 2012						
	Kellokumpu-Lehtinen 2013						
	Lehtonen 2022						
	Petrioli 2011						


Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement
 High
 Some concerns
 Low


Supplementary Figure S1: Traffic plot of Risk of Bias Assessment using ROB 2.0



Supplementary Figure S2: Summary Plot of Risk of Bias Assessment




Supplementary Figure S3: Network plot for PSA




Supplementary Figure S4: Netsplit plot for PSA




Supplementary Figure S5: Netheat plot for PSA




Supplementary Figure S6: Funnel plot for PSA



Supplementary Figure S7: Netweight plot for time to treatment failure/progression



Supplementary Figure S8: Netsplit plot for time to treatment failure/progression



Supplementary Figure S9: Funnel plot for time to treatment failure/progression